comparemela.com

Relapsed Refractoryb Cell Lymphoma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Acalabrutinib/Axi-Cel Generates Preliminary Responses in Relapsed/Refractory B-Cell Lymphoma

Early data seen with acalabrutinib plus axi-cel indicate the combination’s feasibility as bridging therapy in relapsed/refractory B-cell lymphoma.

Division of hematologyUniversity of washington school medicineFred hutchinson cancer centerCellular therapyChristina pohWashington schoolDren bioAcalabrutinib plus axi celRelapsed refractoryb cell lymphoma

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Little rockUnited statesUniversity of arkansasAakash mukherjeeDepartment of internal medicineCollege of medicineWinthropp rockefeller cancer instituteWinthropp rockefeller cancer institute transplant centerCancer institute transplant centerCancer instituteMedical sciencesInternal medicineContributing kiteRelapsed refractoryb cell lymphomaPatients with relapsed refractory diffuse largeb cell lymphomaScholar 1 study

FDA Grants Fast Track Designation to IMPT-314 for Relapsed/Refractory B-cell Lymphoma

The FDA has granted a fast track designation to the CAR T-cell therapy IMPT-314 for the treatment of patients with B-cell–mediated malignancies.

Los angelesUnited statesSumant ramachandraUniversity of californiaJonsson comprehensive cancer centerComprehensive cancer centerNon hodgkin lymphomaFast track designationRelapsed refractoryb cell lymphomaImpt 314

vimarsana © 2020. All Rights Reserved.